Xiaomin Wan

11PUBLICATIONS
1CO-AUTHORS
Regenerative medicine (incl. stem cells)Cancer therapy (excl. chemotherapy and radiation therapy)Medical biotechnology diagnostics (incl. biosensors)Gene and molecular therapyCross-sectional analysis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Aug 12, 2026
Resmetirom for noncirrhotic metabolic dysfunction-associated steatohepatitis with liver fibrosis: establishing a value-based price in China, the UK, France, and Germany.

|Jul 16, 2026
Cost-Effectiveness of Epcoritamab Plus Lenalidomide and Rituximab Versus Lenalidomide and Rituximab for Relapsed/Refractory Follicular Lymphoma: A US Payer Perspective.

|May 10, 2025
Economic evaluation of Erdafitinib as a second-line treatment for advanced metastatic urothelial carcinoma: real-world data from the USA and prospective analysis from China.

Andong Li, Meiyu Wu, Ouyang Xie

|Feb 21, 2025
Sequential biologic therapy in the treatment of active psoriatic arthritis in China: a cost-effectiveness analysis.

Ouyang Xie, Meiyu Wu, Andong Li

|Jan 09, 2025
Biologics in the treatment of active Psoriatic arthritis in China: a network meta-analysis and cost-effectiveness analysis.

Ouyang Xie, Meiyu Wu, Andong Li

|Sep 02, 2024
Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study.

Meiyu Wu, Jing Ma, Sini Li

Pageof 2

Frequent Collaborators

1 joint publications

Yongtao He